ESTAHealthcare · Medical DevicesThe 9 Wall Street analysts covering Establishment Labs Holdings, Inc. hold a median 12-month price target of $105 — +32.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 76 of 100 as at 13 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Establishment Labs Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (93): Sales and profits are climbing, and climbing faster than before.
Issuance (18): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on ESTA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +32.1% from it.
Of the 20 most recent actions, 6 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 7 Aug 2026 | JP Morgan | Maintains | Overweight | $84 → $95 |
| 6 Aug 2026 | BTIG | Maintains | Buy | $96 → $103 |
| 6 Aug 2026 | Needham | Maintains | Buy | $86 → $95 |
| 3 Aug 2026 | TD Cowen | Maintains | Buy | $95 → $117 |
| 15 July 2026 | Mizuho | Maintains | Outperform | — |
| 15 July 2026 | Mizuho | Maintains | Outperform | $100 → $105 |
| 8 July 2026 | Citigroup | Maintains | Neutral | $76 → $92 |
| 8 July 2026 | Citigroup | Maintains | Neutral | — |
| 7 May 2026 | BTIG | Maintains | Buy | — |
| 29 Apr 2026 | BTIG | Reiterates | Buy | — |
| 11 Mar 2026 | Citigroup | Maintains | Neutral | — |
| 26 Feb 2026 | Canaccord Genuity | Maintains | Buy | — |
| 25 Feb 2026 | Mizuho | Maintains | Outperform | — |
| 25 Feb 2026 | Stephens & Co. | Maintains | Overweight | — |
| 24 Feb 2026 | BTIG | Maintains | Buy | — |
| 24 Feb 2026 | Needham | Maintains | Buy | — |
| 12 Jan 2026 | Needham | Reiterates | Buy | — |
| 31 Dec 2025 | BTIG | Maintains | Buy | — |
| 17 Dec 2025 | Canaccord Genuity | Maintains | Buy | — |
| 17 Dec 2025 | JP Morgan | Maintains | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ESTA appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 98% of US stocks
Cheaper than 15% of US stocks
Cheaper than 1% of US stocks
Cheaper than 98% of US stocks
Higher than 79% of US stocks
Higher than 68% of US stocks
Higher than 83% of US stocks
Higher than 27% of US stocks
Higher than 17% of US stocks
Higher than 8% of US stocks
Higher than 34% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Establishment Labs Holdings, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Establishment Labs Holdings Inc. (ESTA) released the transcript of its Q2 2026 earnings call, as published on Seeking Alpha. The document covers the company's second-quarter 2026 financial results and management discussion.
Why it matters — A transcript of the Q2 2026 earnings call gives ESTA watchers direct insight into the company's latest quarterly performance and management commentary.
Establishment Labs reported second-quarter revenue growth of 31.7% year over year, driven by rapid expansion in the United States, rising adoption of its Minimally Invasive platform, and improving operating leverage, as highlighted in its Q2 earnings call.
Why it matters — ESTA watchers would note the continued U.S. expansion and Minimally Invasive platform adoption as indicators of the company's recent business momentum and operational progress.
Establishment Labs Holdings reported a Q2 loss of $0.39 per share, wider than the Zacks Consensus Estimate of a $0.34 loss but narrower than the $0.57 per-share loss from a year earlier. The company topped revenue estimates for the quarter.
Why it matters — ESTA watchers would care because the results show improved year-over-year losses and revenue exceeding expectations, though the per-share loss came in wider than analysts had predicted.
Establishment Labs Holdings Inc. reported financial results for the second quarter ended June 30, 2026, with revenue of $67.5 million, up 31.7% from Q2 2025 and 12.8% sequentially from Q1 2026. US sales reached $24.7 million, up 26% from the prior quarter.
Why it matters — The company's year-over-year and sequential revenue growth provides ESTA watchers with a current snapshot of demand for its breast aesthetics and reconstruction products.
The 9 Wall Street analysts covering Establishment Labs Holdings, Inc. have a median 12-month price target of $105, with estimates ranging from $92 to $117. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 9 analysts covering Establishment Labs Holdings, Inc., 9 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Establishment Labs Holdings, Inc. 76 out of 100 across roughly 4,600 US stocks as at 13 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 13 Aug 2026, Establishment Labs Holdings, Inc. ranks 76 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (93 of 100).
No one can know that. What the data says: the median 12-month target from 9 analysts implies +32.1% from the last close, and Ticker Nerd's factor model ranks Establishment Labs Holdings, Inc. 76 out of 100 as at 13 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Establishment Labs Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ESTA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $92 to $117 over the next 12 months.
Establishment Labs Holdings, Inc. returned +109.4% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Establishment Labs Holdings Inc. is a medical technology company that manufactures and markets medical devices for aesthetic and reconstructive plastic surgeries.
The most recent item we track (Seeking Alpha, 6 Aug 2026): "Establishment Labs Holdings Inc. (ESTA) Q2 2026 Earnings Call Transcript". Establishment Labs Holdings Inc. (ESTA) released the transcript of its Q2 2026 earnings call, as published on Seeking Alpha. The document covers the company's second-quarter 2026 financial results and management discussion.
Establishment Labs Holdings Inc. is a medical technology company that manufactures and markets medical devices for aesthetic and reconstructive plastic surgeries. Its primary products include silicone gel-filled breast implants and body-shaping implants under the renowned Motiva Implants brand, featuring advanced technologies such as SilkSurface, SmoothSilk, VelvetSurface, ProgressiveGel, TrueMonobloc, BluSeal, Divina, Ergonomix, and others. The company also offers breast tissue expanders to support surgical procedures. Establishment Labs Holdings Inc. distributes its innovative implants through direct sales to physicians, hospitals, and clinics, as well as via medical distributors worldwide. Its operations span key geographical segments including Europe, Latin America, Asia-Pacific/Middle East, and other regions, serving professionals in the aesthetic and reconstructive sectors. Founded in 2004 and headquartered in Austin, Texas, Establishment Labs Holdings Inc. plays a vital role in advancing minimally invasive cosmetic procedures and body contouring solutions within the global medical devices market.
CEO Mr. Fillipo Peter Caldini · 1,004 employees · United States · https://www.establishmentlabs.com